文献速递肝病消化道出血消化内镜

卡维地洛联合食管静脉曲张套扎术预防Child-Turcotte-Pugh B级和C级肝硬化高危食管静脉曲张患者首次静脉曲张出血:CAVARLY试验

Combination of carvedilol with variceal band ligation in prevention of first variceal bleed in Child-Turcotte-Pugh B and C cirrhosis with high-risk oesophageal varices: the 'CAVARLY TRIAL'.
PubMed 文献 · Gut · 2024-10-07

该前瞻性试验将330例Child-Turcotte-Pugh B级和C级肝硬化伴高危食管静脉曲张患者分为卡维地洛组、套扎组和联合组各110例,主要终点为12个月首次静脉曲张出血发生率。联合组较套扎组和卡维地洛组均显著降低首次出血发生率,1年死亡率联合组最低。

要点

  • 联合组较套扎组显著降低首次静脉曲张出血发生率(HR 0.37,95%CI 0.192至0.716,p<0.003)。
  • 联合组较卡维地洛组显著降低首次静脉曲张出血发生率(HR 0.31,95%CI 0.163至0.578,p<0.001)。
  • 1年死亡率联合组最低(卡维地洛组20%、套扎组14.5%、联合组6.3%,p=0.012)。

核心结论

  • 在Child-Turcotte-Pugh B级和C级肝硬化伴高危静脉曲张患者中,卡维地洛联合套扎术在静脉曲张出血一级预防方面比任一单药治疗更有效。

研究设计与样本

  • 前瞻性研究,纳入330例Child-Turcotte-Pugh B级和C级肝硬化伴高危静脉曲张患者,每组110例,分别接受卡维地洛(A组)、套扎术(B组)或联合治疗(C组)。
  • 主要终点为12个月首次静脉曲张出血发生率的降低;次要终点包括总死亡率、出血相关死亡率、新发失代偿、肝静脉压力梯度变化和治疗相关不良事件。
  • 试验注册号NCT03069339。

主要发现

  • 患者以男性为主(85.2%),年龄51.4±10.5岁,CTP评分8.87±1.24,MELD评分15.17±3.35,HVPG 16.96±3.57 mm Hg。
  • 1年静脉曲张出血总体发生率为23.8%(n=78)。
  • 意向性分析显示,联合组(C组)较B组显著降低首次静脉曲张出血发生率(HR 0.37,95%CI 0.192至0.716,p<0.003),降幅62.9%;较A组显著降低(HR 0.31,95%CI 0.163至0.578,p<0.001),降幅69.3%。
  • 总死亡率为13.6%(45/330);1年死亡率C组最低(A、B、C组分别为20%、14.5%、6.3%,p=0.012)。
  • A组与C组间HVPG下降(20.8% vs 25.1%,p=0.54)及卡维地洛无应答率(53.4% vs 41.25%,p=0.154)无差异;新发腹水、自发性细菌性腹膜炎、休克、急性肾损伤及出血后器官衰竭发生率组间相当。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Beta-blockers and endoscopic variceal band ligation (VBL) have been preferred therapies for primary prophylaxis of variceal bleeding. However, the choice of therapy in patients with advanced liver disease with high-risk varices is not clear. A comparison of these therapies alone or in combination to prevent the first variceal bleed in advanced cirrhosis patients was carried out. DESIGN: 330 Child-Turcotte-Pugh (CTP) B and C cirrhosis patients, with 'high-risk' varices were prospectively enrolled (n=110 per group) to receive carvedilol (group A), VBL (group B) or combination (group C). Primary endpoint was reduction in the incidence of first variceal bleed at 12 months. The secondary endpoints included overall mortality, bleed-related mortality, new-onset decompensation, change in hepatic vein pressure gradient (HVPG) and treatment-related adverse events. RESULTS: The patients were predominantly males (85.2%), aged 51.4±10.5 years with CTP score of 8.87±1.24, MELD score 15.17±3.35 and HVPG-16.96±3.57 mm Hg. The overall incidence of variceal bleed was 23.8% (n=78) at 1 year. Intention-to-treat analysis showed that the combination arm (group C) significantly reduced the incidence of first variceal bleed by 62.9% as compared with group B (HR 0.37, 95% CI 0.192 to 0.716, p<0.003) and by 69.3% as compared with group A (HR 0.31, 95% CI 0.163 to 0.578, <0.001). The overall mortality was 13.6% (45/330). The 1-year mortality in group C was lowest among the three groups (A, B, C=20%, 14.5%, 6.3%, p=0.012). Reduction in HVPG (20.8% vs 25.1%, p=0.54) and the rate of non-response to carvedilol (53.4% vs 41.25%, p=0.154) were not different between group A and C patients. The incidence of new-onset ascites, spontaneous bacterial peritonitis, shock, and acute kidney injury and postbleed organ failure was also comparable between the groups. CONCLUSION: In CTP B and C cirrhosis patients with high-risk varices, combination of carvedilol and VBL is more effective than either therapy alone, for primary prevention of variceal bleeding. TRIAL REGISTRATION NUMBER: NCT03069339.

来源:Gut,查看原文。版权归原作者所有。

引用

  1. Tevethia HV, Pande A, Vijayaraghavan R, et al. Combination of carvedilol with variceal band ligation in prevention of first variceal bleed in Child-Turcotte-Pugh B and C cirrhosis with high-risk oesophageal varices: the 'CAVARLY TRIAL'. Gut. 2024. PMID: 39067870. doi:10.1136/gutjnl-2023-331181

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。